Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine how pain relief is modified when the investigators combine the Virtual Reality based Snow World game with certain pain medications.
This is a randomized, double-blind, placebo-controlled, within subject 2x2 factorial, repeated measures study. Research participants will play two versions of the Virtual Reality based video game "Snow World" and be given thermal and electrical stimulus. Each of two study visits will be identical with the exception of whether or not the participant will receive an iv infusion of a low dose pain medication or a saline placebo.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Low-dose pain medication | Active Comparator | 80min IV infusion of a low-dose pain medication |
|
| saline placebo | Placebo Comparator | 80min IV infusion of a saline placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low-dose pain medication (Ketalar) and saline placebo | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pain responses between placebo and the low-dose pain medication while playing Snow World. We will assess pain responses with subjective questionnaires concerning the participant's experience while playing Snow World. | Conclusion of 120 study visits. Each participant will spend a total of 8 hours with us. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christine Hoffer, BA | Contact | 206-616-3075 | hoffer@uw.edu |
| Name | Affiliation | Role |
|---|---|---|
| Samuel Sharar, MD | University of Washington | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Washington | Recruiting | Seattle | Washington | 98195 | United States |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Apr 7, 2023 | |
| Reset | May 2, 2023 | |
| Release | Jul 20, 2023 | |
| Reset | Aug 10, 2023 | |
| Release | Aug 23, 2023 | |
| Reset | Sep 18, 2023 | |
| Release | Apr 16, 2026 | |
| Reset | May 7, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Apr 7, 2023 | May 2, 2023 | |||
| Jul 20, 2023 |
| ID | Term |
|---|---|
| D000082 | Acetaminophen |
| D007649 | Ketamine |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Aug 10, 2023 |
| Aug 23, 2023 | Sep 18, 2023 |
| Apr 16, 2026 | May 7, 2026 |
| Aniline Compounds |
| D000588 | Amines |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |